Chris Lau
All posts from Chris Lau
Chris Lau in Value Stocks,

​Biotech Buyout Bonanza

The biotech rout ended. Pfizer (PFE) is buying Anacor for $5.2 billion. Anacor’s drug for eczema, crisaborole, could make $2 billion. The drug is currently under FDA review. Anacor is up 54% today.

Brace yourselves for a move up for the following companies:

  • Regeneron (RGEN) – current $30,000+ IL drug treatment for eczema scheduled to reach market next year.
  • Allergan (AGN) – Pfizer-AGN nixed deal removed the premium on AGN’s stock. Now at a discount, markets may bid AGN higher over time
  • Teva Pharma (TEVA) – completion of acquisition for AGN’s Generics unit